MA52874A - Formulations/compositions comprenant de l'ibrutinib - Google Patents
Formulations/compositions comprenant de l'ibrutinibInfo
- Publication number
- MA52874A MA52874A MA052874A MA52874A MA52874A MA 52874 A MA52874 A MA 52874A MA 052874 A MA052874 A MA 052874A MA 52874 A MA52874 A MA 52874A MA 52874 A MA52874 A MA 52874A
- Authority
- MA
- Morocco
- Prior art keywords
- formulations
- compositions including
- including ibrutinib
- ibrutinib
- compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 2
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title 1
- 229960001507 ibrutinib Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dispersion Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18177987 | 2018-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52874A true MA52874A (fr) | 2021-04-21 |
Family
ID=62684687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052874A MA52874A (fr) | 2018-06-15 | 2019-06-14 | Formulations/compositions comprenant de l'ibrutinib |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12201690B2 (fr) |
| EP (1) | EP3806824A1 (fr) |
| JP (2) | JP7695078B2 (fr) |
| KR (2) | KR102844084B1 (fr) |
| CN (2) | CN112292117B (fr) |
| AU (2) | AU2019287282B2 (fr) |
| BR (1) | BR112020024481A2 (fr) |
| EA (1) | EA202190045A1 (fr) |
| MA (1) | MA52874A (fr) |
| MX (2) | MX2020013684A (fr) |
| SG (1) | SG11202012165WA (fr) |
| WO (1) | WO2019238904A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2755094C1 (ru) * | 2020-11-12 | 2021-09-13 | Общество С Ограниченной Ответственностью "Научно-Производственная Компания "Фармасофт" | Лекарственная форма для инъекций в виде раствора и стабилизатор для его приготовления |
| CN117752664A (zh) * | 2023-12-13 | 2024-03-26 | 苏州晶云星空制药有限公司 | 一种包含伊布替尼晶型a的药物组合物及用途 |
| CN119745889A (zh) * | 2024-12-31 | 2025-04-04 | 安徽理工大学 | 一种靶向巨噬细胞依鲁替尼纳米制剂及其制备方法与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| PL1824493T3 (pl) * | 2004-12-06 | 2009-01-30 | Janssen Pharmaceutica Nv | Zawiesina zawierająca meloksykam do podawania doustnego |
| EP2529621B1 (fr) | 2006-09-22 | 2016-10-05 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
| EP2139487B1 (fr) | 2007-03-28 | 2015-11-11 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
| MX380504B (es) | 2010-06-03 | 2025-03-12 | Pharmacyclics Llc | El uso de inhibidores de la tirosina quinasa de bruton (btk). |
| MA37711A1 (fr) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Formes cristallines d'un inhibiteur de tyrosine kinase de bruton |
| WO2014004707A1 (fr) | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprenant de l'ibrutinib |
| WO2015061752A1 (fr) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Traitement à l'aide d'inhibiteurs de la tyrosine kinase de bruton et de l'immunothérapie |
| US10314842B2 (en) * | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| WO2015187848A1 (fr) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Combinaisons d'inhibiteur de hdac et d'inhibiteur de btk |
| BR112017001677A2 (pt) * | 2014-08-01 | 2018-07-17 | Pharmacyclics Llc | biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of proton tyrosine kinase inhibitor |
| MA41828A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton |
| WO2016156127A1 (fr) | 2015-04-02 | 2016-10-06 | Ratiopharm Gmbh | Co-cristaux d'ibrutinib et d'acides carboxyliques |
| EP3892302B8 (fr) * | 2015-04-06 | 2023-10-18 | Janssen Pharmaceutica NV | Compositions contenant de l'ibrutinib |
| DK3405178T3 (da) | 2016-01-19 | 2025-09-22 | Janssen Pharmaceutica Nv | Formuleringer/sammensætninger, der omfatter en btk-inhibitor |
| FI3405177T3 (fi) | 2016-01-19 | 2026-06-03 | Janssen Pharmaceutica Nv | Btk:n estäjää käsittäviä formulaatioita/koostumuksia |
| MX2018014577A (es) * | 2016-05-27 | 2019-05-20 | Tg Therapeutics Inc | Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b. |
-
2019
- 2019-06-14 KR KR1020217000409A patent/KR102844084B1/ko active Active
- 2019-06-14 MX MX2020013684A patent/MX2020013684A/es unknown
- 2019-06-14 EA EA202190045A patent/EA202190045A1/ru unknown
- 2019-06-14 JP JP2020569159A patent/JP7695078B2/ja active Active
- 2019-06-14 AU AU2019287282A patent/AU2019287282B2/en active Active
- 2019-06-14 US US16/441,497 patent/US12201690B2/en active Active
- 2019-06-14 MA MA052874A patent/MA52874A/fr unknown
- 2019-06-14 KR KR1020257026142A patent/KR20250125432A/ko active Pending
- 2019-06-14 CN CN201980039816.6A patent/CN112292117B/zh active Active
- 2019-06-14 BR BR112020024481-3A patent/BR112020024481A2/pt unknown
- 2019-06-14 EP EP19729770.8A patent/EP3806824A1/fr active Pending
- 2019-06-14 SG SG11202012165WA patent/SG11202012165WA/en unknown
- 2019-06-14 CN CN202410614738.0A patent/CN118512397A/zh active Pending
- 2019-06-14 WO PCT/EP2019/065637 patent/WO2019238904A1/fr not_active Ceased
-
2020
- 2020-12-14 MX MX2025015454A patent/MX2025015454A/es unknown
-
2023
- 2023-11-09 JP JP2023191535A patent/JP7853261B2/ja active Active
-
2024
- 2024-12-20 AU AU2024287122A patent/AU2024287122A1/en active Pending
-
2025
- 2025-01-21 US US19/033,026 patent/US20250161456A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN118512397A (zh) | 2024-08-20 |
| EA202190045A1 (ru) | 2021-03-17 |
| SG11202012165WA (en) | 2021-01-28 |
| US12201690B2 (en) | 2025-01-21 |
| JP2024023262A (ja) | 2024-02-21 |
| JP7695078B2 (ja) | 2025-06-18 |
| US20250161456A1 (en) | 2025-05-22 |
| EP3806824A1 (fr) | 2021-04-21 |
| US20190381174A1 (en) | 2019-12-19 |
| AU2024287122A1 (en) | 2025-01-23 |
| JP2021527097A (ja) | 2021-10-11 |
| AU2019287282A1 (en) | 2020-11-26 |
| CN112292117A (zh) | 2021-01-29 |
| KR20210021348A (ko) | 2021-02-25 |
| JP7853261B2 (ja) | 2026-04-28 |
| BR112020024481A2 (pt) | 2021-03-02 |
| KR20250125432A (ko) | 2025-08-21 |
| MX2020013684A (es) | 2021-03-02 |
| CA3100146A1 (fr) | 2019-12-19 |
| KR102844084B1 (ko) | 2025-08-07 |
| WO2019238904A1 (fr) | 2019-12-19 |
| CN112292117B (zh) | 2024-06-07 |
| MX2025015454A (es) | 2026-02-03 |
| AU2019287282B2 (en) | 2024-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4049466A4 (fr) | Estimation d'empreinte de réverbération | |
| MA49421A (fr) | Formulations d'arn | |
| MA49043A (fr) | Formulation stable d'anticorps | |
| EP3746086A4 (fr) | Formulations topiques comprenant du tofacitinib | |
| EP3820490A4 (fr) | Compositions d'aav | |
| EP3823978A4 (fr) | Compositions d'anticorps anti-fcrn | |
| MA54052A (fr) | Formulation d'anticorps | |
| EP3773721A4 (fr) | Formulations d'immunoconjugué anti-cd79b stables | |
| EP3688033A4 (fr) | Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose | |
| MA54139A (fr) | Formulation d'anticorps | |
| EP3740553A4 (fr) | Compositions d'agent conservateur antimicrobien | |
| EP3820980A4 (fr) | Compositions d'esterquats | |
| EP3986415A4 (fr) | Formulations d'ibogaïne | |
| EP4023292A4 (fr) | Formulation d'injection | |
| EP3704757A4 (fr) | Composition d'électrolyte | |
| EP3815692A4 (fr) | Composition de diacide oligosaccharidique d'alginate | |
| EP4054548A4 (fr) | Compositions adhésives comprenant des agents thérapeutiques | |
| EP3976025A4 (fr) | Formulations d'agents d'imagerie psma | |
| EP4013441A4 (fr) | Formulations de larazotide | |
| EP3773574A4 (fr) | Formulations d'amlodipine | |
| PT3765379T (pt) | Composições | |
| EP3903723A4 (fr) | Combiné d'implant dentaire | |
| EP3899996A4 (fr) | Compositions d'électrolyte | |
| EP3977855A4 (fr) | Composition microbicide stable | |
| SG11202012165WA (en) | Formulations/compositions comprising ibrutinib |